{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-030260","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2021-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.827899+00:00","generated_at":"2026-06-28T04:15:30.816398+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Indaptus Therapeutics appoints Mark J. Gilbert to Board, replacing Hoonmo Lee","bullets":["Hoonmo Lee resigned from the Board effective Nov. 29, 2021, with no disagreement.","Board elected Mark J. Gilbert, M.D. as Class I director, term until 2022 annual meeting.","Dr. Gilbert is EVP of R&D at Acepodia, former CMO of Juno Therapeutics.","Dr. Gilbert granted option to purchase 20,000 shares at $5.35/share, vesting in 1 year.","Eligible for annual retainer of $50,000 and additional option grants at each annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-030260","json":"https://secwatch.observer/filing/0001493152-21-030260.json","markdown":"https://secwatch.observer/filing/0001493152-21-030260.md","text":"https://secwatch.observer/filing/0001493152-21-030260.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315221030260/0001493152-21-030260-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315221030260/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T04:15:30.816398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3215d163b2","claim":"Hoonmo Lee resigned as Director at Indaptus Therapeutics, Inc..","evidence_excerpt":"On November 29, 2021, Mr. Hoonmo Lee tendered his resignation from the Board of Directors (the “Board”) of Indaptus Therapeutics, Inc. (the “Company”), and from all committees of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315221030260/0001493152-21-030260-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"bd300d5d65","claim":"Mark J. Gilbert was elected as Director at Indaptus Therapeutics, Inc..","evidence_excerpt":"On the same day, the Board elected Mark J. Gilbert, M.D. as a member of the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315221030260/0001493152-21-030260-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}